J. Schwarze

发表

Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy

B. Neyns, S. Aspeslagh, G. Awada, 2021, Melanoma research.

Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer

M. de Ridder, K. Breckpot, D. Escors, 2015, Oncotarget.

An atypical sarcoid-like reaction during anti-protein death 1 treatment in a patient with metastatic melanoma

B. Neyns, S. Aspeslagh, A. Van Binst, 2020, Melanoma research.

Assessing T-cell responses in anticancer immunotherapy

C. Goyvaerts, K. Breckpot, A. Lanna, 2013, Oncoimmunology.

A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab

B. Neyns, P. van Dam, M. Keyaerts, 2021, Cancers.

Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)

B. Neyns, A. Michotte, P. Theuns, 2020, Journal for ImmunoTherapy of Cancer.

Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial

B. Neyns, S. Tuyaerts, A. Vasaturo, 2022, Journal for ImmunoTherapy of Cancer.

Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma.

B. Neyns, V. del Marmol, R. Van den Begin, 2019, Melanoma research.

A phase 2 clinical trial on trametinib and low-dose dabrafenib in advanced pretreated BRAFV600/NRASQ61R/K/L wild-type melanoma (TraMel-WT): Interim efficacy and safety results.

B. Neyns, H. Everaert, G. Awada, 2021 .

Baseline biomarkers correlated with outcome in advanced melanoma treated with pembrolizumab monotherapy.

S. Ong, S. Warren, B. Neyns, 2020 .

Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab

B. Neyns, M. Keyaerts, H. Everaert, 2018, Annals of Oncology.

C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting

B. Neyns, S. Aspeslagh, G. Awada, 2021, Melanoma research.

Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy

M. Ridder, C. Goyvaerts, K. Breckpot, 2014, Oncoimmunology.

A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors

B. Neyns, V. Kruse, G. Awada, 2022, Melanoma research.

Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1+ Myeloid Dendritic Cells

B. Neyns, J. Aerts, K. Breckpot, 2022, International journal of molecular sciences.

Myeloid-derived suppressor cells reveal radioprotective properties through arginase-induced l-arginine depletion.

G. Storme, T. Gevaert, B. Engels, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

M. Weichenthal, K. Kähler, P. Ascierto, 2022, Journal for ImmunoTherapy of Cancer.

Durable Complete Response of a Recurrent Mesencephalic Glioblastoma Treated with Trametinib and Low-Dose Dabrafenib in a Patient with Neurofibromatosis Type 1

B. Neyns, L. Van De Voorde, J. Duerinck, 2020, Case Reports in Oncology.

Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial

K. Willard-Gallo, B. Neyns, P. Kristanto, 2022, Cancers.

Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial

B. Neyns, S. Tuyaerts, I. Van Riet, 2020, Vaccines.

Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors

C. Blank, B. Neyns, A. Boekhout, 2019, Journal of oncology.

A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT)

B. Neyns, H. Everaert, G. Awada, 2021, Cancers.

Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy

F. Tacke, L. Boon, B. Neyns, 2021, Journal for ImmunoTherapy of Cancer.

Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse

B. Neyns, J. de Mey, I. Willekens, 2021, Cancers.

The clinical application of cancer immunotherapy based on naturally circulating dendritic cells

G. Coukos, B. Neyns, I. Melero, 2019, Journal of Immunotherapy for Cancer.

Current “state of the art” on dendritic cell-based cancer vaccines in melanoma

B. Neyns, S. Tuyaerts, J. Schwarze, 2023, Current opinion in oncology.

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells

B. Neyns, J. Aerts, K. Breckpot, 2021, Frontiers in Immunology.

Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial

I. Salmon, S. Van Dooren, B. Neyns, 2021, Journal for ImmunoTherapy of Cancer.

962MO A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma

B. Neyns, S. Tuyaerts, I. Van Riet, 2021, Annals of Oncology.

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

B. Neyns, V. del Marmol, M. Keyaerts, 2019, Journal of Translational Medicine.

Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab

P. Maruff, C. Leys, B. Neyns, 2020, Journal of immunology research.

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

B. Neyns, V. del Marmol, M. Keyaerts, 2019, Journal of Translational Medicine.

J. Duerinck, J. Schwarze, A. Rogiers, 2024, Journal of neuro-oncology.

Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma

K. Willard-Gallo, S. Tuyaerts, J. Tijtgat, 2024, Journal for ImmunoTherapy of Cancer.